Division of Medical Microbiology and Immunology, University of Stellenbosch, Cape Town, South Africa; National Health Laboratory Service, Tygerberg Hospital, Cape Town, South Africa.
Int J Infect Dis. 2022 Jan;114:115-123. doi: 10.1016/j.ijid.2021.10.056. Epub 2021 Nov 2.
The Xpert MTB/Rif Ultra (Xpert Ultra; Cepheid, USA) has increased sensitivity compared with its predecessor (Gene Xpert), due to the addition of multicopy amplification targets and a novel trace call. The World Health Organization suggests that tuberculosis (TB) treatment should be initiated in HIV, paediatric, and extra-pulmonary TB patients with trace results. However, other factors such as previous TB disease may complicate the interpretation of trace results in high-burden TB settings. This study aimed to clarify the positive predictors for active TB disease in patients with trace results and to investigate if previous TB disease influences TB culture positivity.
A retrospective descriptive study was performed on 290 patients with trace results, to determine what the positive predictors for active TB are by comparing clinical factors to TB culture.
The key findings of this study were that extra-pulmonary TB samples (OR, 2.7; p=0.012), no previous TB disease (OR, 4.5; p=0.001) and symptoms suggestive of TB (OR, 6.4; p<0.001) are independent predictors for active TB disease.
This study found readily available clinical predictors that can aid clinicians with TB management decisions in patients with trace results.
与上一代(Gene Xpert)相比,Xpert MTB/Rif Ultra(Xpert Ultra;Cepheid,美国)由于增加了多拷贝扩增靶标和新的痕量呼叫,其灵敏度有所提高。世界卫生组织建议,在痕量结果的 HIV、儿科和肺外结核病患者中,应启动结核病(TB)治疗。然而,其他因素,如以前的结核病,可能会使高负担结核病环境中痕量结果的解释复杂化。本研究旨在阐明痕量结果患者中活动性结核病的阳性预测因素,并研究以前的结核病是否会影响结核培养阳性率。
对 290 例痕量结果患者进行了回顾性描述性研究,通过比较临床因素与结核培养,确定活动性结核病的阳性预测因素。
这项研究的主要发现是,肺外结核病样本(OR,2.7;p=0.012)、无既往结核病(OR,4.5;p=0.001)和提示结核病的症状(OR,6.4;p<0.001)是活动性结核病的独立预测因素。
本研究发现了一些易于获得的临床预测因素,可以帮助临床医生在痕量结果患者的 TB 管理决策中提供帮助。